While chimeric antigen receptor (CAR) T cell immunotherapy targeting CD19 has shown remarkable success in patients with lymphoid malignancies, the potency of CAR T cells in solid tumors is low so far. To improve the efficacy of CAR T cells targeting prostate carcinoma, we designed a novel CAR that recognizes a new epitope in the prostate-specific membrane antigen (PSMA) and established novel paradigms to apply CAR T cells in a preclinical prostate cancer model. characterization of the D7 single-chain antibody fragment-derived anti-PSMA CAR confirmed that the choice of the co-stimulatory domain is a major determinant of CAR T cell activation, differentiation, and exhaustion. , focal injections of the PSMA CAR T cells eradicated established human prostate cancer xenografts in a preclinical mouse model. Moreover, systemic intravenous CAR T cell application significantly inhibited tumor growth in combination with non-ablative low-dose docetaxel chemotherapy, while docetaxel or CAR T cell application alone was not effective. In conclusion, the focal application of D7-derived CAR T cells and their combination with chemotherapy represent promising immunotherapeutic avenues to treat local and advanced prostate cancer in the clinic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372156 | PMC |
| http://dx.doi.org/10.1016/j.omto.2020.06.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Better, Faster, Stronger: Accelerating mRNA-Based Immunotherapies With Nanocarriers.
Wiley Interdiscip Rev Nanomed Nanobiotechnol
November 2024
Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.
Messenger ribonucleic acid (mRNA) therapeutics are attracting attention as promising tools in cancer immunotherapy due to their ability to leverage the in vivo expression of all known protein sequences. Even small amounts of mRNA can have a powerful effect on cancer vaccines by promoting the synthesis of tumor-specific antigens (TSA) or tumor-associated antigens (TAA) by antigen-presenting cells (APC). These antigens are then presented to T cells, eliciting strong antitumor immune stimulation.
View Article and Find Full Text PDFBispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint inhibition with costimulatory and non-checkpoint targeted therapy.
Expert Opin Biol Ther
December 2024
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immunotherapy and have enhanced the survival of patients with malignant tumors. However, the overall efficacy of ICIs remains unsatisfactory and is faced with two major concerns of resistance development and occurrence of immune-related adverse events (irAEs). Bispecific antibodies (bsAbs) have emerged as promising strategies with unique mechanisms of action to achieve a better efficacy and safety than monoclonal antibodies (mAbs) or even their combination.
View Article and Find Full Text PDFDNA origami assembled spheroid for evaluating cytotoxicity and infiltration of chimeric antigen receptor macrophage (CAR-M).
Commun Biol
October 2024
RocRock Biotechnology Co. Ltd, Suzhou, China.
Article Synopsis
- CAR T-cell therapies have been effective for blood cancers but face challenges in treating solid tumors; CAR-macrophages (CAR-M) are being explored as an alternative therapy.*
- CAR-M can be activated and target tumors using tumor-associated antigens, but the mechanisms of their movement and infiltration in tumors are not fully understood.*
- This study uses a 3D tumor spheroid model created from self-assembling nucleic acid nanostructures to evaluate CAR-M's effectiveness, showing better invasion and tumor-killing abilities compared to traditional 2D models.*
Muc16CD is a novel CAR T cell target antigen for the treatment of pancreatic cancer.
Mol Ther Oncol
December 2024
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Article Synopsis
- - Pancreatic cancer is a tough-to-treat disease with only a 13% survival rate over five years, and current immunotherapies like CAR T cells aren't very effective for it.
- - Researchers identified Muc16CD as a new target (tumor-associated antigen) that CAR T cells can attack, which is present in pancreatic tumors.
- - Muc16CD-targeted CAR T cells show promise in laboratory models, effectively recognizing pancreatic tumor cells and improving tumor control and survival rates.
TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity.
Mol Ther
November 2024
Cellectis Inc, New York, NY 10016, USA. Electronic address:
Adoptive cell therapy using chimeric antigen receptor (CAR) T cells has proven to be lifesaving for many cancer patients. However, its therapeutic efficacy has been limited in solid tumors. One key factor for this is cancer-associated fibroblasts (CAFs) that modulate the tumor microenvironment (TME) to inhibit T cell infiltration and induce "T cell dysfunction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!